Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (21-30 of 172) with videos related to

Pageof 18
Sort By:
Rheumatology (Oxford, England)|December 11, 2012
ACR/EULAR 2010 rheumatoid arthritis classification criteriaJonathan Kay, Katherine S Upchurch
Annals of the Rheumatic Diseases|August 28, 2016
Clinical trials of biosimilars should become more similarJonathan Kay, John D Isaacs
Nature Reviews. Rheumatology|June 2, 2017
Pharmacotherapy: Biosimilar switching - "To set a form upon desired change"Jonathan Kay, Kevin L Winthrop
The New England Journal of Medicine|October 14, 2005
Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiencyJonathan Kay, Robert T McCluskey
Nature Reviews. Rheumatology|April 24, 2013
Rheumatoid arthritis: erosion defined: back to basicsJonathan Kay, Ellen M Gravallese
Current Rheumatology Reports|July 22, 2008
Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicityDerrick J Todd, Jonathan Kay
Core Evidence|August 10, 2010
Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritisJonathan Kay, Mahboob U Rahman
Current Rheumatology Reports|February 20, 2003
Advanced glycation endproducts and osteoarthritisDeborah M Saudek, Jonathan Kay
Annals of the Rheumatic Diseases|July 31, 2013
Biosimilars to treat inflammatory arthritis: the challenge of proving identityJonathan Kay, Josef S Smolen
Rheumatology (Oxford, England)|December 11, 2012
Evolution of treatment for rheumatoid arthritisKatherine S Upchurch, Jonathan Kay
Pageof 18

Showing results (21-30 of 172) with videos related to

Sort By:
Pageof 18
Rheumatology (Oxford, England)|December 11, 2012
ACR/EULAR 2010 rheumatoid arthritis classification criteriaJonathan Kay, Katherine S Upchurch
Annals of the Rheumatic Diseases|August 28, 2016
Clinical trials of biosimilars should become more similarJonathan Kay, John D Isaacs
Nature Reviews. Rheumatology|June 2, 2017
Pharmacotherapy: Biosimilar switching - "To set a form upon desired change"Jonathan Kay, Kevin L Winthrop
The New England Journal of Medicine|October 14, 2005
Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiencyJonathan Kay, Robert T McCluskey
Nature Reviews. Rheumatology|April 24, 2013
Rheumatoid arthritis: erosion defined: back to basicsJonathan Kay, Ellen M Gravallese
Current Rheumatology Reports|July 22, 2008
Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicityDerrick J Todd, Jonathan Kay
Core Evidence|August 10, 2010
Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritisJonathan Kay, Mahboob U Rahman
Current Rheumatology Reports|February 20, 2003
Advanced glycation endproducts and osteoarthritisDeborah M Saudek, Jonathan Kay
Annals of the Rheumatic Diseases|July 31, 2013
Biosimilars to treat inflammatory arthritis: the challenge of proving identityJonathan Kay, Josef S Smolen
Rheumatology (Oxford, England)|December 11, 2012
Evolution of treatment for rheumatoid arthritisKatherine S Upchurch, Jonathan Kay
Pageof 18